Oncology & Cancer

New review on p53 biology and reactivation in blood cancers

In a recently published review in the journal Biomarker Research, Joanna Zawacka, Docent at the department of Oncology-Pathology discusses our current understanding of p53 biology in myelodysplastic syndrome (MDS) and acute ...

Oncology & Cancer

Medicare approves genetic test for solid tumors

A genetic test that identifies cancer mutations in solid tumors and that was developed by researchers at Washington University School of Medicine in St. Louis has been approved for reimbursement by the Centers for Medicare ...

page 1 from 4

The myelodysplastic syndromes (MDS, formerly known as preleukemia) are a diverse collection of hematological (blood-related) medical conditions that involve ineffective production (or dysplasia) of the myeloid class of blood cells.

Patients with MDS often develop severe anemia and require frequent blood transfusions. In most cases, the disease worsens and the patient develops cytopenias (low blood counts) due to progressive bone marrow failure. In about one third of patients with MDS, the disease transforms into acute myelogenous leukemia (AML), usually within months to a few years.

The myelodysplastic syndromes are all disorders of the stem cell in the bone marrow. In MDS, hematopoiesis (blood production) is disorderly and ineffective. The number and quality of blood-forming cells decline irreversibly, further impairing blood production.

This text uses material from Wikipedia licensed under CC BY-SA